Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Montenegro
Czech Republic
Denmark
Estonia
Spain
Kosovo
Lithuania
Latvia
Luxembourg
Macedonia
Germany
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Switzerland
Sweden
Turkey
Hungary
United Kingdom
Italy
UAE
Hong Kong
Kuwait
Lebanon
South Africa
Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 801 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 77 |
| 802 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 23 |
| 803 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 804 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 53 |
| 805 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 75 |
| 806 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 807 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 8 |
| 808 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 809 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 38 |
| 810 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 811 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 69 |
| 812 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 31 |
| 813 | Bone Marrow Family | Allogeneic | Acute Myleogenous Leukemia, alloPBST 7/2025 | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 814 | Bone Marrow | Allogeneic | Aplastic Anemia | Hematology | 2025 | Standard Therapy | Spain | 15 |
| 815 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Norway | 55 |
| 816 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 3 |
| 817 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 7 |
| 818 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Ukraine | 36 |
| 819 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 10 |
| 820 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 76 |
| 821 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 39 |
| 822 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | South Africa | 6 |
| 823 | Bone Marrow | Allogeneic | Wiskott-Aldrich syndrome | Hematology | 2025 | Standard Therapy | Turkey | 6 |
| 824 | Bone Marrow | Allogeneic | Combined immnunodeficiency | Hematology | 2025 | Standard Therapy | Ukraine | 3 |
| 825 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2025 | Standard Therapy | Poland | 3 |
| 826 | Bone Marrow | Allogeneic | Mixed Phenotype Acute Leukemia | Hematology | 2025 | Standard Therapy | Poland | 13 |
| 827 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 7 |
| 828 | Bone Marrow | Allogeneic | B-cell precursor Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 829 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 43 |
| 830 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 19 |
| 831 | Bone Marrow | Allogeneic | Very Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 12 |
| 832 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 833 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 10 |
| 834 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 6 |
| 835 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 44 |
| 836 | Bone Marrow | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria | Hematology | 2025 | Standard Therapy | Poland | 25 |
| 837 | Bone Marrow | Allogeneic | Juvenile Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 4 |
| 838 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 21 |
| 839 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 12 |
| 840 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Hungary | 10 |
| 841 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Czechia | 68 |
| 842 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2025 | Standard Therapy | Poland | 53 |
| 843 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 4 |
| 844 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | France | 4 |
| 845 | Bone Marrow | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria | Hematology | 2025 | Standard Therapy | Norway | 18 |
| 846 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Spain | 24 |
| 847 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Belarus | 5 |
| 848 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 849 | Bone Marrow | Allogeneic | diamond-Balckfan anemia | Hematology | 2025 | Standard Therapy | Germany | 11 |
| 850 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 57 |
| 851 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 852 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | France | 3 |
| 853 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belarus | 1 |
| 854 | Bone Marrow | Allogeneic | pB-Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 15 |
| 855 | Bone Marrow | Allogeneic | OHID XIAP – Other Histiocytic Disorders / X-Linked Inhibitor of Apoptosis Protein | Hematology | 2025 | Standard Therapy | Switzerland | 2 |
| 856 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 46 |
| 857 | Bone Marrow | Allogeneic | Acquired Idiopathic Sideroblastic Anemia | Hematology | 2025 | Standard Therapy | Russian Federation | 5 |
| 858 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 10 |
| 859 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 47 |
| 860 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | CROATIA | 11 |
| 861 | Bone Marrow | Allogeneic | Juvenile myelomonocytic leukemia | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 862 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Brazil | 12 |
| 863 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Australia | 8 |
| 864 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 3 |
| 865 | Bone Marrow | Allogeneic | Myelodysplatic Syndrome | Hematology | 2025 | Standard Therapy | USA | 60 |
| 866 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Russia | 36 |
| 867 | Bone Marrow | Allogeneic | Thalassemia major | Hematology | 2025 | Standard Therapy | Turkey | 10 |
| 868 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 58 |
| 869 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 2 |
| 870 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 18 |
| 871 | Bone Marrow | Allogeneic | Other Non-Malignant Disease, Specify | Hematology | 2025 | Standard Therapy | USA | 17 |
| 872 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 15 |
| 873 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 15 |
| 874 | Bone Marrow | Allogeneic | aplastic anemia | Hematology | 2025 | Standard Therapy | Belgium | 36 |
| 875 | Bone Marrow | Allogeneic | Primary Refractory | Hematology | 2025 | Standard Therapy | Ireland | 27 |
| 876 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 39 |
| 877 | Bone Marrow | Allogeneic | Sickle Cell Disease (SCD) | Hematology | 2025 | Standard Therapy | Italy | 8 |
| 878 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 68 |
| 879 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 880 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 1 |
| 881 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2025 | Standard Therapy | United Kingdom | 13 |
| 882 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Denmark | 38 |
| 883 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 17 |
| 884 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2025 | Standard Therapy | Poland | 11 |
| 885 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 9 |
| 886 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 3 |
| 887 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | France | 9 |
| 888 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2025 | Standard Therapy | Poland | 8 |
| 889 | Bone Marrow | Allogeneic | Immune Deficiency | Hematology | 2025 | Standard Therapy | United Kingdom | 10 |
| 890 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 12 |
| 891 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 20 |
| 892 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Turkey | 17 |
| 893 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 13 |
| 894 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Canada | 22 |
| 895 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 15 |
| 896 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Italy | 8 |
| 897 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 3 |
| 898 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 2 |
| 899 | Bone Marrow | Allogeneic | Bone Marrow Failure | Hematology | 2025 | Standard Therapy | Netherlands | 23 |
| 900 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2025 | Standard Therapy | Italy | 6 |